MX368036B - Particulas inhalables que comprenden tiotropio e indacaterol. - Google Patents
Particulas inhalables que comprenden tiotropio e indacaterol.Info
- Publication number
- MX368036B MX368036B MX2016001539A MX2016001539A MX368036B MX 368036 B MX368036 B MX 368036B MX 2016001539 A MX2016001539 A MX 2016001539A MX 2016001539 A MX2016001539 A MX 2016001539A MX 368036 B MX368036 B MX 368036B
- Authority
- MX
- Mexico
- Prior art keywords
- inhalable particles
- indacaterol
- tiotropium
- weight
- relates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a partículas inhalables que comprenden una mezcla íntima que consiste en a) un compuesto de tiotropio amorfo, b) un compuesto de indacaterol amorfo y c) un derivado de azúcar, en las cuales el peso del derivado de azúcar está comprendido desde 0 hasta 85% con respecto al peso de las partículas inhalables. También se refiere a una composición farmacéutica que comprende las partículas inhalables de la invención, a un procedimiento para su preparación y a su uso en el tratamiento de asma o enfermedad pulmonar obstructiva crónica (EPOC).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13382318 | 2013-08-05 | ||
PCT/EP2014/066750 WO2015018800A1 (en) | 2013-08-05 | 2014-08-04 | Inhalable particles comprising tiotropium and indacaterol |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2016001539A MX2016001539A (es) | 2016-07-13 |
MX368036B true MX368036B (es) | 2019-09-17 |
Family
ID=48985714
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016001539A MX368036B (es) | 2013-08-05 | 2014-08-04 | Particulas inhalables que comprenden tiotropio e indacaterol. |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP3030224B1 (es) |
BR (1) | BR112016002222A2 (es) |
ES (1) | ES2726831T3 (es) |
MX (1) | MX368036B (es) |
RU (1) | RU2016107798A (es) |
WO (1) | WO2015018800A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200215051A1 (en) | 2019-01-03 | 2020-07-09 | Glenmark Specialty S.A. | Nebulization composition comprising tiotropium and indacaterol |
CN114191418B (zh) * | 2021-12-21 | 2023-06-09 | 丽珠医药集团股份有限公司 | 噻托溴铵双层微球及其制备方法和噻托溴铵缓释吸入剂 |
WO2023192445A1 (en) * | 2022-03-30 | 2023-10-05 | Aerorx Therapeutics Llc | Liquid formulations of indacaterol and glycopyrronium |
CN117233286A (zh) * | 2023-09-19 | 2023-12-15 | 南京力成药业有限公司 | 一种噻托溴铵的定量检测方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7250426B2 (en) * | 2002-11-29 | 2007-07-31 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Tiotropium-containing pharmaceutical combination for inhalation |
RU2568882C2 (ru) * | 2010-07-16 | 2015-11-20 | Сипла Лимитед | Фармацевтические композиции |
GB201113662D0 (en) * | 2011-08-08 | 2011-09-21 | Prosonix Ltd | Pharmaceutical compositions |
-
2014
- 2014-08-04 RU RU2016107798A patent/RU2016107798A/ru not_active Application Discontinuation
- 2014-08-04 BR BR112016002222A patent/BR112016002222A2/pt not_active IP Right Cessation
- 2014-08-04 EP EP14749773.9A patent/EP3030224B1/en not_active Not-in-force
- 2014-08-04 MX MX2016001539A patent/MX368036B/es active IP Right Grant
- 2014-08-04 ES ES14749773T patent/ES2726831T3/es active Active
- 2014-08-04 WO PCT/EP2014/066750 patent/WO2015018800A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
BR112016002222A2 (pt) | 2017-08-01 |
RU2016107798A3 (es) | 2018-06-05 |
WO2015018800A1 (en) | 2015-02-12 |
RU2016107798A (ru) | 2017-09-14 |
EP3030224B1 (en) | 2019-02-27 |
MX2016001539A (es) | 2016-07-13 |
ES2726831T3 (es) | 2019-10-09 |
EP3030224A1 (en) | 2016-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2897464C (en) | Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide | |
MY194850A (en) | (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase i inhibitors | |
UA112296C2 (uk) | Сухий порошковий препарат, який містить інгібітор фосфодіестерази | |
WO2012110770A3 (en) | Combination of glycopyrrolate and a beta2 -agonist | |
PH12017502087B1 (en) | Tiotropium inhalation solution for nebulization | |
MY159172A (en) | Inhalable particles comprising tiotropium | |
WO2014016548A3 (en) | Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient | |
EA201590030A1 (ru) | Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы, и третий компонент | |
MX368036B (es) | Particulas inhalables que comprenden tiotropio e indacaterol. | |
EP2682097A3 (en) | Dry Powder Inhalers Comprising A Carrier Other Than Lactose | |
EA201201397A1 (ru) | Ингалятор, содержащий расслаиваемую блистерную упаковку | |
UA115989C2 (uk) | Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії | |
EA201591871A1 (ru) | Фармацевтическая композиция, содержащая будесонид и формотерол | |
EA029678B9 (ru) | Четвертичные соли пиперидиния | |
WO2019098969A3 (en) | Dry powder compositions for inhalation | |
BR112015004810A2 (pt) | preparações de tiotrópio | |
MX2019004366A (es) | Composiciones nebulizables de tiotropio y formoterol. | |
TR200909788A2 (tr) | Tiotropyum içeren inhalasyona uygun kuru toz formülasyonu | |
MY191295A (en) | Pharmaceutical composition containing budesonide and formoterol | |
TN2011000121A1 (en) | Inhalable particles comprising tiotropium | |
TR201716199A1 (tr) | Arformoterol ve ipratropium içeren yeni farmasötik bileşimler. | |
EA201991113A1 (ru) | Способы лечения аутоиммунных, респираторных и воспалительных расстройств ингаляцией n-оксида рофлумиласта | |
TN2013000015A1 (en) | Dry powder formulation comprising a phosphodiesterase inhibitor | |
WO2014062143A3 (en) | Combinations of glycopyrrolate and an anticholinergic agent | |
TR201716209A2 (tr) | Arformoterol ve umeklidinyum içeren yeni farmasötik bileşimler. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |